Innovent Biologics, a leading biopharmaceutical company developing therapies across oncology, autoimmune, cardiovascular, metabolic, and ophthalmology areas, announced that its partner Ollin Biosciences reported positive topline results from the Phase 1b JADE study. The randomized, head-to-head trial evaluated IBI324, also known as OLN324, a next-generation VEGF/Ang2 bispecific antibody, against faricimab in more than 160 patients with diabetic macular edema or wet age-related macular degeneration. OLN324’s design allows for up to sixty times greater anti-Ang2 potency, a smaller protein format, and a higher molar dose, creating a differentiated profile that could position it as a first-line therapy in retinal diseases.
Health Technology Insights: Adagio Medical Adds Executives to Boost ULTC Launch
In patients with diabetic macular edema, OLN324 showed faster and more pronounced retinal drying compared to faricimab. Patients receiving a 4 mg dose of OLN324 experienced a mean reduction in central subfield thickness of seventy-nine microns at Week 1, compared with forty-five microns for faricimab, representing an approximate seventy-five percent improvement. By Week 12, the reduction was one hundred eighty microns versus one hundred twenty-one microns, a fifty percent greater improvement for OLN324. Nearly ninety percent of OLN324-treated patients achieved complete absence of edema at Week 12, defined as central subfield thickness below three hundred twenty-five microns, compared to fifty-seven percent of patients treated with faricimab.
Health Technology Insights: Connecticut HIE Adopts PIQXL Gateway to Boost Data Quality
Patients with wet age-related macular degeneration across all treatment groups achieved similar anatomic improvements, with early reductions in central subfield thickness visible by Week 1 and maintained through Week 12. Visual outcomes measured by best-corrected visual acuity showed rapid and sustained gains in all groups, with OLN324 demonstrating numerically higher improvements at Week 12 for both diabetic macular edema and wet AMD.
Arshad M. Khanani, Managing Partner and Director of Clinical Research at Sierra Eye Associates and investigator of the JADE study, said diabetic macular edema is a challenging condition and a proving ground for therapies expected to become standard of care. He emphasized that the speed and magnitude of retinal drying observed with OLN324 compared to faricimab is clinically meaningful and could support broad application across major retinal diseases in real-world practice.
Jason Ehrlich, Co-founder and Chief Executive Officer of Ollin Biosciences, stated that OLN324 is the first therapy to show superior anatomic efficacy over faricimab in a randomized head-to-head trial. He explained that the combination of higher potency, higher molar dose, and smaller bispecific format allows OLN324 to fully exploit dual VEGF and Ang2 inhibition, potentially establishing a new standard of care in the global $15 billion retinal therapeutics market.
Dr. Lei Qian, Chief R&D Officer of Innovent Biologics, praised the JADE trial results and highlighted OLN324’s potential to deliver meaningful clinical value in retinal diseases. He noted that Innovent looks forward to continuing collaboration with Ollin to advance the global development of the drug. Dr. Ehrlich added that Ollin intends to present the JADE study data to health authorities and proceed rapidly into global Phase 3 trials for both diabetic macular edema and wet age-related macular degeneration.
Previous Phase 1 studies in Chinese patients confirmed OLN324’s potential, showing favorable safety and promising vision and anatomic improvements. The therapy was discovered by Innovent and is being developed in partnership with Ollin. Ollin plans to present further details of the JADE trial and pipeline updates at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026.
Health Technology Insights: ACCO Brands to Acquire EPOS
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
